Volume 18, Issue 4, Pages (June 2015)

Slides:



Advertisements
Similar presentations
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)— Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication.
Advertisements

A Meta-Analysis of Osteoporotic Fracture Risk with Medication Nonadherence Susan Ross, MD, FRCPC, Ebony Samuels, PhD, Kerry Gairy, MSc, Sheikh Iqbal, MD,
Program-Specific Cost-Effectiveness Analysis: Breast Cancer Screening Policies for a Safety-Net Program Joy Melnikow, MD, MPH, Daniel J. Tancredi, PhD,
Cost-Effectiveness of Incobotulinumtoxin-A with Flexible Treatment Intervals Compared to Onabotulinumtoxin-A in the Management of Blepharospasm and Cervical.
Cost-Effectiveness of Sensor-Augmented Pump Therapy in Adults with Type 1 Diabetes in the United States Shital Kamble, PhD, Kevin A. Schulman, MD, Shelby.
Cost-Effectiveness of Partially Hydrolyzed Whey Protein Formula in the Primary Prevention of Atopic Dermatitis in At-Risk Urban Filipino Infants Abhijeet.
Bendamustine Versus Chlorambucil for the First-Line Treatment of Chronic Lymphocytic Leukemia in England and Wales: A Cost-Utility Analysis Beth Woods,
Volume 14, Issue 8, Pages (December 2011)
Value in Health Regional Issues
Ulcerative Colitis Treatment Patterns and Cost of Care
Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual.
Volume 15, Issue 8, Pages (December 2012)
Volume 18, Issue 5, Pages (July 2015)
Mapping the COPD Assessment Test onto EQ-5D
The association between the severity of poststroke depression and clinical outcomes after first-onset stroke in Korean patients  Geun-Young Park, M.D.,
Tai Chi Exercise for Cancer-Related Fatigue in Patients With Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial  Li-Li Zhang, RN, Su-Zhen.
Volume 15, Issue 1, Pages S20-S28 (January 2012)
Volume 14, Issue 4, Pages (June 2011)
Volume 17, Issue 8, Pages (December 2014)
Volume 14, Issue 4, Pages (June 2011)
Volume 15, Issue 6, Pages (September 2012)
Multidomain Patient-Reported Outcomes of Irritable Bowel Syndrome: Exploring Person-Centered Perspectives to Better Understand Symptom Severity Scores 
Volume 17, Issue 2, Pages (March 2014)
Examining the Value of Menopausal Symptom Relief Among US Women
Volume 17, Issue 2, Pages (March 2014)
Value in Health Regional Issues
Eric Nsiah-Boateng, MPH, Moses Aikins, PhD 
Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.
Tai Chi Exercise for Cancer-Related Fatigue in Patients With Lung Cancer Undergoing Chemotherapy: A Randomized Controlled Trial  Li-Li Zhang, RN, Su-Zhen.
Value in Health Regional Issues
Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future?  Emmanuel Ankrah Odame, MBCHB, MPH  Value in.
Association of p53 Codon 72 Genotypes and Clinical Outcome in Human Papillomavirus-Infected Lung Cancer Patients  Shih-Pin Chen, MD, Nan-Yung Hsu, MD,
Value in Health Regional Issues
The Process of Privatization of Health Care Provision in Poland
Boxiong Tang, MD, PhD, Eran Harary, MD, Ricky Kurzman, MSc, Joaquín F
Clinical Implication of Blood Levels of B-Type Natriuretic Peptide in Pediatric Patients on Mechanical Circulatory Support  Shu-Chien Huang, MD, En-Ting.
Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,
Value in Health Regional Issues
Prognostic Variables in Thoracic Esophageal Squamous Cell Carcinoma
Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore  Vivianne Shih, PharmD, BCOP, BCPS, Alexandre Chan, PharmD,
Assessment of Effect of Diabetes on Health-Related Quality of Life in Patients with Coronary Artery Disease Using the EQ-5D Questionnaire  Bhavik Shah,
Jinhyun Kim, PhD, Eunhee Lee, PhD, Sungjae Kim, PhD, Tae Jin Lee, PhD 
The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel 
Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD 
Omneya Mohamed, PhD, David H. Kreling, PhD 
Patient Utility Measurement for Managing Ureteral Stones: A Modified Standard Gamble Approach  Ching-Yuan Fann, PhD, Po-Chien Huang, MD, MS, Amy Ming-Fang.
Onur Baser, MS, PhD, Akif Altinbas, MD, Erdem Baser, MS, M
Analysis of Excess Direct Medical Costs of Vision Impairment in Taiwan
Value in Health Regional Issues
Value in Health Regional Issues
Transforming Public Servants’ Health Care Organization in Greece through the Implementation of an Electronic Referral Project  Kyriakos Souliotis, PhD,
Economic Burden of Individual Suffering from Atrial Fibrillation–Related Stroke in China  Shanlian Hu, MSc, Lin Zhan, MSc, Bao Liu, MD, PhD, Yue Gao, MD,
Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?  Chun-Ru Chien, MD, PhD, Ya-Chen Tina.
Economic Evaluation of Pravastatin for Primary Prevention of Coronary Artery Disease Based on Risk Prediction from JALS-ECC in Japan  Yoshie Onishi, MS,
Use of the EQ-5D Instrument and Value Scale in Comparing Health States of Patients in Four Health Care Programs among Health Care Providers  Valentina.
Volume 69, Issue 10, Pages (May 2006)
Pei Wang, PhD, Nan Luo, PhD, E.S. Tai, PhD, Julian Thumboo, PhD 
Guidance Document: Global Pharmacoeconomic Model Adaption Strategies
Value in Health Regional Issues
Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea  Ji Haeng Heo, MS, Karen L.
Dossier System as a Practical Tool for Compiling Reimbursement Lists
Value in Health Regional Issues
Evaluating the Long-Term Health Economic Implications of Improving the Proportion of Patients with Type 2 Diabetes Meeting Treatment Targets in Mexico 
Social Cost of Substance Abuse in Russia
A Comparison of 1-Year Treatment Costs in Patients with Type 2 Diabetes Following Initiation of Insulin Glargine or Insulin Detemir in Argentina  Joaquín.
Cost-Effectiveness Analysis of Omalizumab for the Treatment of Severe Asthma in Japan and the Value of Responder Prediction Methods Based on a Multinational.
Economic Impact of Venous Thromboembolism Following Major Orthopaedic Surgery in Japan  Shinro Takai, MD, PhD, Masao Akagi, MD, PhD, Bruce Crawford, MA,
Disability in Patients With Degenerative Lumbar Spinal Stenosis
Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD 
The Role of Video-Assisted Thoracoscopic Surgery in Therapeutic Lung Resection for Pulmonary Tuberculosis  Yi-Ting Yen, MD, Ming-Ho Wu, MD, Wu-Wei Lai,
Presentation transcript:

Volume 18, Issue 4, Pages 396-403 (June 2015) Responder Definition of a Patient-Reported Outcome Instrument for Laryngopharyngeal Reflux Based on the US FDA Guidance  Han-Chung Lien, MD, MPH, Chen-Chi Wang, MD, Shou-Wu Lee, MD, Jeng-Yuan Hsu, MD, Hong-Zen Yeh, MD, Chung-Wang Ko, MD, Chi-Sen Chang, MD, PhD, Wen-Miin Liang, PhD  Value in Health  Volume 18, Issue 4, Pages 396-403 (June 2015) DOI: 10.1016/j.jval.2015.01.001 Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 1 Mean changes in RSI scores from baseline between patients with 50% or more and less than 50% reduction in the primary laryngeal symptom at week 12. (The “I” bars represent standard error.) RSI, Reflux Symptom Index. Value in Health 2015 18, 396-403DOI: (10.1016/j.jval.2015.01.001) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

Fig. 2 Illustrative cumulative distribution function shows a distinct difference in cumulative percentage at the RSI score reduction of six points from baseline between patients with 50% or more and less than 50% reduction in the primary laryngeal symptom at week 12. (X-axis, the RSI score change from baseline; Y-axis, cumulative percentage of patients; Sensitivity, cumulative percentage for patients with ≥50% reduction in the primary laryngeal symptom; Specificity, 1 − cumulative percentage for patients with <50% reduction in the primary laryngeal symptom). RSI, Reflux Symptom Index. Value in Health 2015 18, 396-403DOI: (10.1016/j.jval.2015.01.001) Copyright © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions